Non-hormonal treatments for managing vulvovaginal atrophy/genitourinary syndrome of menopause

References

• Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87–94.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass MLS; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063–1068. Oct
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509–522.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cancer [Internet]. World Health Organization. 2022 [cited 2023 Jan 29]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.
   Google Scholar
• American Society of Clinical Oncology. Breast Cancer – Statistics [Internet]. Cancer.net. 2015. [cited 2023 Jan 29]. Available from: https://www.cancer.net/cancer-types/breast-cancer/statistics/2015.
   Google Scholar
• Cancer Research UK. Breast cancer statistics [Internet]. Cancer Research UK. 2015. [cited 2023 Jan 29]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer#heading-Three.
   Google Scholar
• Potter N, Panay N. Vaginal lubricants and moisturizers: a review into use, efficacy, and safety. Climacteric. 2021;24(1):19–24.
   PubMed Web of Science ®Google Scholar
• Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151–161.
   PubMed Web of Science ®Google Scholar
• Cox P, Panay N. Vulvovaginal atrophy in women after cancer. Climacteric. 2019;22(6):565–571.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Use and procurement of additional lubricants for male and female condoms: WHO/UNFPA/FHI360: advisory note [Internet]. apps.who.int. 2012. Available from: https://apps.who.int/iris/handle/10665/76580.
   Google Scholar
• Djapardy V, Panay N. Alternative and non-hormonal treatments to symptoms of menopause. Best Pract Res Clin Obstet Gynaecol. 2022;81:45–60.
   PubMedGoogle Scholar
• Mitchell CM, Reed SD, Diem S, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms. JAMA Intern Med. 2018;178(5):681–690.
   PubMed Web of Science ®Google Scholar
• Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4(7):528–539.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Martella S, Albani F, et al. Hyaluronic acid: a valid therapeutic option for early management of genitourinary syndrome of menopause in cancer survivors? Healthcare. 2022;10(8):1528.
   Web of Science ®Google Scholar
• Nappi RE, Kotek M, Brešt’anský A, et al. Effectiveness of hyaluronate-based pessaries in the treatment of vulvovaginal atrophy in postmenopausal women. Climacteric. 2020;23(5):519–524.
   PubMed Web of Science ®Google Scholar
• dos Santos CCM, Uggioni MLR, Colonetti T, et al. Hyaluronic acid in postmenopause vaginal atrophy: a systematic review. J Sex Med. 2021;18(1):156–166. Jan
   PubMed Web of Science ®Google Scholar
• Gold D, Nicolay L, Avian A, et al. Vaginal laser therapy versus hyaluronic acid suppositories for women with symptoms of urogenital atrophy after treatment for breast cancer: a randomized controlled trial. Maturitas. 2023;167:1–7.
   PubMed Web of Science ®Google Scholar
• Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81(2):629–683. https://www.ncbi.nlm.nih.gov/pubmed/11274341/
   PubMed Web of Science ®Google Scholar
• Ghorbani Z, Mirghafourvand M. The efficacy and safety of intravaginal oxytocin on vaginal atrophy: a systematic review. Post Reprod Health. 2021;27(1):30–41.
   PubMedGoogle Scholar
• Zohrabi I, Abedi P, Ansari S, et al. The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial. BMC Women’s Health. 2020;20(1):108.
   PubMed Web of Science ®Google Scholar
• Torky HA, Taha A, Marie H, et al. Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial. Climacteric. 2018;21(2):174–178.
   PubMed Web of Science ®Google Scholar
• Santos LPA, Bonduki CE, Dardes RDCDM, et al. Effects of oxytocin versus promestriene on genitourinary syndrome: a pilot, prospective, randomized, double-blind study. Clinics (Sao Paulo). 2022;77:100116.
   PubMed Web of Science ®Google Scholar
• Zipper R, Lamvu G. Vaginal laser therapy for gynecologic conditions: re-examining the controversy and where do we go from here. J Comp Eff Res. 2022;11(11):843–851.
   PubMed Web of Science ®Google Scholar
• Alvisi S, Lami A, Baldassarre M, et al. Short-term efficacy and safety of non-ablative laser treatment alone or with estriol or moisturizers in postmenopausal women with vulvovaginal atrophy. J Sex Med. 2022;19(5):761–770.
   Web of Science ®Google Scholar
• Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2018;25(1):21–28.
   PubMed Web of Science ®Google Scholar
• Pessoa LdL, Sarmento ACA, Medeiros KS, et al. Efficacy and safety of laser therapy for the treatment of genitourinary syndrome of menopause: a protocol for systematic review and meta-analysis of clinical trials. Front Reprod Health. 2021;3:772690.
   PubMedGoogle Scholar
• Li FG, Maheux-Lacroix S, Deans R, et al. Effect of fractional carbon dioxide laser vs sham treatment on symptom severity in women with postmenopausal vaginal symptoms. JAMA. 2021;326(14):1381–1389.
   PubMed Web of Science ®Google Scholar
• Mension E, Alonso I, Anglès-Acedo S, et al. Effect of fractional carbon dioxide vs sham laser on sexual function in survivors of breast cancer receiving aromatase inhibitors for genitourinary syndrome of menopause. JAMA Netw Open. 2023;6(2):e2255697.
   PubMed Web of Science ®Google Scholar
• Page A, Verbakel JY, Verhaeghe J, et al. Laser versus sham for genitourinary syndrome of menopause: a randomised controlled trial. BJOG. 2023;130(3):312–319.
   PubMed Web of Science ®Google Scholar
• Palacios S. Ospemifene for vulvar and vaginal atrophy: an overview. DIC. 2020;9:1–5.
   Google Scholar
• Russo E, Misasi G, Montt-Guevara MM, et al. Effects of ospemifene on overactive bladder in postmenopausal women with vulvovaginal atrophy. Climacteric. 2023;1–5.
   Web of Science ®Google Scholar
• Castelo-Branco C, Mension E, Torras I, et al. Treating genitourinary syndrome of menopause in breast cancer survivors: main challenges and promising strategies. Climacteric. 2023;1–6.
   PubMed Web of Science ®Google Scholar
• Pingarrón Santofímia C, Lafuente González P, Guitiérrez Vélez MDC, et al. Long-term use of ospemifene in clinical practice for vulvo-vaginal atrophy: end results at 12 months of follow-up. Gynecol Endocrinol. 2022;38(7):577–582.
   PubMed Web of Science ®Google Scholar
• Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part I: evaluation of efficacy. Maturitas. 2019;121:86–92.
   PubMed Web of Science ®Google Scholar
• Maffei S, Guiducci L. Effect of ospemifene on densitometric and plasma bone metabolism biomarkers in postmenopausal women reporting vulvar and vaginal atrophy (VVA). JCM. 2022;11(21):6316.
   Google Scholar
• Goldstein SR, Neven P, Cummings S, et al. Postmenopausal evaluation and risk reduction with lasofoxifene (PEARL) trial. Menopause. 2011;18(1):17–22.
   PubMed Web of Science ®Google Scholar
• Paton DM. Ospemifene for the treatment of dyspareunia in postmenopausal women. Drugs Today (Barc). 2014;50(5):357–364.
   PubMed Web of Science ®Google Scholar
• Cai B, Simon J, Villa P, et al. No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA). Maturitas. 2020;142:38–44. Dec
   PubMed Web of Science ®Google Scholar
• Garzon S, Apostolopoulos V, Stojanovska L, et al. Non-oestrogenic modalities to reverse urogenital aging. Prz Menopauzalny. 2021;20(3):140–147.
   PubMedGoogle Scholar